Sanger sequencing in routine KRAS testing: A review of 1720 cases from a pathologist's perspective

Journal of Clinical Pathology

Volumn 65, Issue 10, 2012, Pages 940-944

  Malapelle, Umberto ^a   Bellevicine, Claudio ^a   Salatiello, Maria ^a   De Luca, Caterina ^a   Rispo, Elisabetta ^a   Riccio, Palmira ^b   Sparano, Lucianna ^b   De Stefano, Alfonso ^a   Carlomagno, Chiara ^a   Maiello, Francesco Maria ^c   Vita, Giulia ^d   Nappi, Oscar ^e   Troncone, Giancarlo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Anatomia Patologica   (Italy)

^c Ospedale dei Pellegrini   (Italy)

^d REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^e CARDARELLI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; K RAS PROTEIN;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; MALE; METASTASIS; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SANGER SEQUENCING; TISSUE FIXATION; TREATMENT RESPONSE; TUMOR GENE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, RAS; HUMANS; MALE; MIDDLE AGED; MUTATION;

EID: 84866886114     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2012-200773     Document Type: Article

References (22)

1. van Krieken JH, Jung A, Kirchner T, et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 2008;453:417-31.
2. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008;358:1160-74.
3. Tol J, Punt CJ. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin Ther 2010;32:437-53.
4. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
5. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009;27:2091-6.
6. Weichert W, Schewe C, Lehmann A, et al. KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. J Mol Diagn 2010;12:35-42.
7. Bellon E, Ligtenberg MJ, Tejpar S, et al. External quality assessment for KRAS testing is needed: setup of a european program and report of the first joined regional quality assessment rounds. Oncologist 2011;16:467-78.
8. Angulo B, Garcia-Garcia E, Martinez R, et al. A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations. A morphology-based approach in colorectal carcinoma. J Mol Diagn 2010;12:292-9.
9. Cross J. DxS Ltd. Pharmacogenomics 2008;9:463-7. (Pubitemid 351803928)
10. Do H, Krypuy M, Mitchell PL, et al. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer 2008;8:142.
11. Franklin WA, Haney J, Sugita M, et al. KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer. J Mol Diagn 2010;12:43-50.
12. Kwon MJ, Lee SE, Kang SY, et al. Frequency of KRAS, BRAF, and PIK3CA mutations in advanced colorectal cancers: comparison of peptide nucleic acid-mediated PCR clamping and direct sequencing in formalin-fixed, paraffin-embedded tissue. Pathol Res Pract 2011;207:762-8.
13. Tol J, Dijkstra JR, Vink-Borger ME, et al. High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. J Cell Mol Med 2010;14:2122-31.
14. Malapelle U, de Rosa N, Rocco D, et al. EGFR and KRAS mutations detection on lung cancer liquid-based cytology: a pilot study. J Clin Pathol 2012;65:87-91.
15. Kamel-Reid S, Zhang T, Persons DL, et al. Validation of KRAS testing for anti-EGFR therapeutic decisions for patients with metastatic colorectal carcinoma. Arch Pathol Lab Med 2012;136:26-32.
16. Kobunai T, Watanabe T, Yamamoto Y, et al. The frequency of KRAS mutation detection in human colon carcinoma is influenced by the sensitivity of assay methodology: a comparison between direct sequencing and real-time PCR. Biochem Biophys Res Commun 2010;395:158-62.
17. Longo DL. Tumor heterogeneity and personalized medicine. N Engl J Med 2012;366:956-7.
18. Baldus SE, Schaefer KL, Engers R, et al. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010;16:790-9.
19. Kotoula V, Charalambous E, Biesmans B, et al. Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics. PLoS One 2009;4:e7746.
20. Krol LC, t Hart NA, Methorst N, et al. Concordance in KRAS and BRAF mutations in endoscopic biopsy samples and resection specimens of colorectal adenocarcinoma. Eur J Cancer 2012;48:1108-15.
21. Yang QH, Schmidt J, Soucy G, et al. KRAS mutational status of endoscopic biopsies matches resection specimens. J Clin Pathol 2012;65:604-7.
22. Van Cutsem E, Kohne CH, Lang I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29:2011-19.